I wanted to find five foreign, profitable companies that investors would find worthwhile. They would have to be cheap stocks with low price-earnings ratios and high dividend yields. The idea is that by diversifying a portion of your portfolio in non-U.S. stocks, you will enhance your overall returns.Often, foreign equities provide a return that is not correlated with U.S. stocks. At least, that is the theory. There are some significant drawbacks. I have managed non-U.S. equity portfolios on the institutional side for a good number of years and am well familiar with these issues.For one, non-U.S. stocks are subject to currency fluctuations. When the dollar rises, the U.S. dollar return on non-U.S. equities tends to lag. However, I have learned that this effect tends to recycle over a number of years and sort of washes out.InvestorPlace - Stock Market News, Stock Advice & Trading TipsA second issue is that often, non-U.S....
(Bloomberg) -- The pound is back to being the pariah of the currency world as renewed Brexit risks worsen the troubles of a market still reeling from the shock of the pandemic.Sterling fell a fifth day against the dollar on Friday after the latest negotiations between the U.K. and the European Union seemed set for a stalemate, with Britain’s chief Brexit negotiator David Frost saying “very limited progress” was made toward a pact. His EU counterpart Michel Barnier said that the two sides’ positions remain extremely divergent.British Prime Minister Boris Johnson has threatened to walk away from the talks this week if enough progress wasn’t made. That raises the risk that the U.K. will end its transition period on Dec. 31 without a free-trade deal -- putting further strain on an economy that’s already facing the worst recession in three centuries. The pound is already the past month’s worst-performing Group-of-10 currency...
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 14) * Allogene Therapeutics Inc (NASDAQ: ALLO)(reacted to ASCO abstract) * Altimmune Inc (NASDAQ: ALT)(announced first-quarter results and update to its COVID-19 vaccine program) * BioXcel Therapeutics Inc (NASDAQ: BTAI)( announced full enrollment of Phase 3 trials evaluating BXCL501 for the acute treatment of agitation in patients with schizophrenia and bipolar disorder and said it expects results from the two studies in July) * Co-Diagnostics Inc (NASDAQ: CODX) * Myokardia Inc (NASDAQ: MYOK) * Repligen Corporation (NASDAQ: RGEN) * Translate Bio Inc (NASDAQ: TBIO) * VBI Vaccines Inc (NASDAQ: VBIV)Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 14) * Genfit SA (NASDAQ: GNFT) * Lyra Therapeutics Inc (NASDAQ: LYRA) (IPOed May 1) * RA Medical Systems Inc (NYSE: RMED)(reacted to first-quarter results) * Recro Pharma Inc...
(Bloomberg) -- U.S. equity futures turned lower on further signs of strained relations between America and China and ahead of more economic data. European stocks rose as investors weighed the latest figures on the spread of the coronavirus.Contracts on the three main U.S. equity gauges reversed earlier gains shortly after Reuters reported the country is moving to block global chipmakers from supplying Chinese telecom giant Huawei Technologies Co. The Stoxx Europe 600 also trimmed its advance on the news, though it remained higher as Italy edged toward allowing free movement and Germany reported a drop in new infections. Crude headed for a third weekly gain amid signs the oil market is slowly rebalancing. Flaring U.S.-China tensions have hung over markets all week, and President Donald Trump said in remarks broadcast Thursday that he doesn’t want to talk to his Chinese counterpart Xi Jinping right now. Stress between the nations is an...
